Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Dutasteride significantly improves quality of life measures in patients with enlarged prostate

Prostate Cancer and Prostatic Diseases volume 11, pages 129–133 (2008)Cite this article

Abstract

The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Roehrborn CG, Marks L, Harkaway R . Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 2006; 9: 30–34.

    Article  CAS  PubMed  Google Scholar 

  2. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarette R et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267–273.

    Article  PubMed  Google Scholar 

  3. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM . Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277–284.

    Article  CAS  PubMed  Google Scholar 

  4. Arocho R, McMillan CA, Sutton-Wallance P . Construct validation of the USA–Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998; 7: 121–126.

    Article  CAS  PubMed  Google Scholar 

  5. Spencer S, Calverly PM, Sherwood Burge P, Jones PW, for the ISOLDE Study Group. Inhaled steroids in obstructive lung disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122–128.

    Article  CAS  PubMed  Google Scholar 

  6. Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825–831.

    Article  CAS  PubMed  Google Scholar 

  7. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA, on behalf of the Primary Care Investigator Study Group. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther 1997; 19: 243–258.

    Article  CAS  PubMed  Google Scholar 

  8. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557–563.

    Article  CAS  PubMed  Google Scholar 

  9. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, on behalf of the ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–441.

    Article  PubMed  Google Scholar 

  10. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S . Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179.

    Article  CAS  PubMed  Google Scholar 

  11. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–1557.

    Article  CAS  PubMed  Google Scholar 

  12. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK . Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33 (4 Suppl): AS145–AS155.

    CAS  PubMed  Google Scholar 

  13. Epstein RS, Deverka PA, Chute CG, Panser L, Oesterling JE, Lieber MM et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431–1445.

    Article  CAS  PubMed  Google Scholar 

  14. Chapple CR . Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004; 94: 738–744.

    Article  PubMed  Google Scholar 

  15. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N . Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005; 96: 572–577.

    Article  PubMed  Google Scholar 

  16. Roehrborn CG, O'Leary M, Black L . Measurement of the effect of dutasteride on worry and embarrassment associated with lower urinary tract symptoms in men with BPH: use of a novel instrument [poster]. Presented at the European Association of Urology 2005 Meeting, 19 March 2005 Istanbul, Turkey.

    Google Scholar 

  17. O'Leary MP, Roehrborn C, Andriole G, Nikel C, Boyle P, Höfner K . Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 2003; 92: 262–266.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge Grace Johnson, PharmD, Scientific Therapeutics Information Inc, Springfield, New Jersey, and thank her for providing editorial assistance in preparing this manuscript. Phase III studies and preparation of this manuscript were funded by GlaxoSmithKline.

Author information

Authors and Affiliations

  1. Brigham and Women's Hospital, Boston, MA, USA

    M P O'Leary

  2. Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA

    C G Roehrborn

  3. Global Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA

    L Black

Authors
  1. M P O'Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C G Roehrborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Black
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M P O'Leary.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Leary, M., Roehrborn, C. & Black, L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis 11, 129–133 (2008). https://doi.org/10.1038/sj.pcan.4500990

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500990

Keywords

This article is cited by

Search

Advanced search

Quick links